For a study, it was determined that a typical non-motor characteristic of Parkinson’s disease (PD) was REM sleep behavior disorder (RBD). Cannabidiol (CBD) was a non-psychoactive component of Cannabis sativa that provided an alternate treatment for RBD. The effectiveness and safety of CBD for RBD in Parkinson’s disease were investigated. In 33 individuals with RBD and PD, researchers conducted a phase II/III, double-blind, placebo-controlled clinical study. Patients were randomly assigned to receive CBD in dosages ranging from 75 to 300mg or a placebo capsule for 14 weeks. The frequency of nights with RBD, CGI-I, and CGI-S were the key outcomes. CBD had no effect on primary outcomes when compared to a placebo. In terms of secondary outcomes, researchers found a substantial increase in average sleep satisfaction in the CBD vs placebo groups from the fourth to eighth week, with P=0.049 and P=0.038, respectively. CB, as an additional medication, had no effect on RBD symptoms in Parkinson’s disease patients. With a dosage of 300mg, there was a temporary improvement in sleep satisfaction.